Neurology Biomarkers Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 2.4 billion
Estimated Base Value
2035 Forecast
US$ 8.2 billion
Projected Market Value
CAGR 2026–2035
13.1%
Compound Annual Growth
Largest Segment
Amyloid Beta Biomarkers
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
Quanterix
Emerging Players
Alto Neuroscience, Neurotrack Technologies
Neurology Biomarkers Market Overview
The Neurology Biomarkers Market encompasses the research, development, and commercialization of biological indicators used to detect, diagnose, monitor, and predict neurological diseases and therapeutic responses. This market includes molecular, imaging, physiological, and genetic biomarkers applied across conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Key purchasers include pharmaceutical and biotechnology companies, diagnostic laboratories, and academic research institutions, all seeking to advance drug discovery, facilitate clinical trials, and enable personalized medicine approaches in neurological care.
The market is estimated at $2.4 Bn in 2025 and is forecast to reach $8.2 Bn in 2035, growing at a CAGR of 13.1% from 2025 to 2035. Demand is driven by the rising prevalence of neurological diseases and increased R&D funding for neurological therapies, alongside technological advancements in biomarker identification. However, high development and validation costs, coupled with a lack of standardization, present restraints to market expansion.
The market is segmented by Type (e.g., Amyloid Beta, Tau Protein), Technology (e.g., Immunoassays, Mass Spectrometry), Application (e.g., Alzheimer's Disease, Parkinson's Disease), End-User (e.g., Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories), Source (e.g., Cerebrospinal Fluid, Blood), and Product & Service (e.g., Assay Kits, Analyzers & Instruments). Key regions include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Quanterix, C2N Diagnostics, and Denali Therapeutics. The full report provides detailed analysis across these segments and regions.
Market Definition & Overview
The Neurology Biomarkers Market involves the comprehensive research, development, validation, and commercialization of biological indicators used to detect, diagnose, monitor, and predict neurological diseases and therapeutic responses. This market spans molecular, imaging, physiological, and genetic biomarkers applied across various neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. It serves pharmaceutical companies, biotechnology firms, and diagnostic providers in advancing drug discovery, facilitating clinical trials, stratifying patients, and enabling personalized medicine approaches to neurological care. The market aims to improve diagnostic accuracy, track disease progression, and assess the efficacy and safety of new neurological therapeutics.
Scope
- Global geographic coverage, analyzing key regions and countries.
- Analysis by biomarker type, disease indication, end-user, and technology.
- Focus on pharmaceutical R&D and diagnostic applications within neurology.
- Market sizing and forecast from 2025 to 2035.
Inclusions
- Molecular biomarkers (e.g., proteins, nucleic acids) for neurological disorders.
- Imaging biomarkers and associated contrast agents for CNS diseases.
- Genetic and proteomic services specific to neurological conditions.
- Diagnostic assays and kits explicitly for neurological biomarker detection.
- Companion diagnostics developed for neurological drug therapies.
- Bioinformatics and data analysis solutions for neurological biomarker data.
Exclusions
- Sales of approved neurological therapeutic drugs themselves.
- General medical device market not specific to biomarker detection.
- Non-neurology specific biomarker research or applications.
- Basic research reagents not primarily for biomarker validation.
- Clinical laboratory testing without a dedicated biomarker focus.
Market Size Forecast
Executive Summary
• The Neurology Biomarkers market is valued at $2.4 Bn in 2025 and is forecast to reach $8.2 Bn by 2035, reflecting a robust CAGR of 13.1% as demand accelerates across every major segment and region over the ten-year outlook.
• Amyloid Beta Biomarkers leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying competitive pressures are driving strategic M&A and collaborative partnerships, consolidating diagnostic platforms and leveraging AI-driven analytics for biomarker discovery, particularly impacting early detection in neurodegenerative conditions.
• Aging global demographics and precision medicine imperatives are profoundly accelerating demand for validated neurology biomarkers, shifting paradigms towards earlier intervention and personalized therapeutic strategies for neurological disorders globally.
• Breakthroughs in liquid biopsy techniques and advanced neuroimaging, coupled with evolving regulatory pathways emphasizing companion diagnostics, fundamentally transform biomarker development, enabling non-invasive detection and monitoring solutions.
• While North America and Europe lead in innovation and adoption, emerging Asian markets present substantial long-term growth opportunities, demanding localized validation and cost-effective solutions for diverse healthcare infrastructures and patient populations.
• Significant venture capital and pharmaceutical R&D investments increasingly flow into biomarker platforms focused on multiplex assays and digital solutions, signaling a strategic shift towards integrated diagnostic pipelines and advanced data interpretation capabilities.
• The market's forward trajectory indicates a profound shift from prognostic to predictive and theranostic applications, with AI-driven analytics and multi-omic data integration becoming crucial for unlocking next-generation personalized neurology treatments.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Neurology Biomarkers Market was valued at $2.4 billion in the base year, reflecting a significant established presence in the pharmaceuticals sector.
Robust Growth Outlook
The market is projected to achieve substantial growth, reaching $8.2 billion by the forecast year, indicating strong future expansion.
Impressive CAGR
This rapid market expansion is driven by an impressive Compound Annual Growth Rate (CAGR) of 13.1% over the forecast period.
Alzheimer's Dominance
The Alzheimer's disease segment is expected to remain a leading contributor to market revenue, fueled by ongoing research and increasing diagnostic demand.
North American Lead
North America is anticipated to maintain its position as the leading region, supported by extensive research funding and advanced healthcare infrastructure.
Non-Invasive Trend
A notable trend is the increasing focus on the development and adoption of non-invasive biomarkers for earlier and more accurate neurological disease detection and monitoring.
Market Dynamics
Market Trends
- Increasing adoption of blood-based and other non-invasive biomarkers.
- Artificial intelligence and machine learning are revolutionizing biomarker discovery.
- Focus on multi-modal biomarker panels for enhanced diagnostic accuracy.
- Growing emphasis on early detection of neurological diseases.
Growth Drivers
- Rising global prevalence of debilitating neurological diseases.
- Significant increase in R&D funding for neurological therapies.
- Rapid technological advancements in biomarker identification and validation.
- Aging global population drives demand for neurodegenerative diagnostics.
Restraints
- High development and validation costs limit market entry.
- Lack of standardization hinders widespread adoption and comparability.
- Complex regulatory pathways delay biomarker approval and commercialization.
- Difficulty in identifying specific and sensitive biomarkers remains a challenge.
Opportunities
- Developing biomarkers for currently untreatable or rare neurological conditions.
- Expansion into therapeutic monitoring and companion diagnostics.
- Leveraging digital biomarkers from wearables for remote patient insights.
- Significant growth potential in emerging global healthcare markets.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Amyloid Beta BiomarkersTau Protein BiomarkersAlpha-Synuclein BiomarkersNeurofilament Light Chain BiomarkersCerebrospinal Fluid BiomarkersBlood BiomarkersGenetic BiomarkersInflammatory Biomarkers |
| By Technology | ImmunoassaysMass SpectrometryChromatographyNext-Generation SequencingPolymerase Chain ReactionFlow CytometryIn Situ Hybridization |
| By Application | Alzheimer's DiseaseParkinson's DiseaseMultiple SclerosisHuntington's DiseaseAmyotrophic Lateral SclerosisTraumatic Brain InjuryStrokeNeuro-Oncology |
| By End-User | Pharmaceutical & Biotechnology CompaniesDiagnostic LaboratoriesAcademic & Research InstitutionsHospitals & ClinicsContract Research Organizations |
| By Source | Cerebrospinal FluidBloodUrineSalivaTissue BiopsyHair Follicles |
| By Product & Service | Assay KitsReagents & ConsumablesAnalyzers & InstrumentsSoftware & Bioinformatics ToolsBiomarker Discovery ServicesContract Research Services |
Regional Analysis
- North America leads the neurology biomarkers market, propelled by extensive R&D, high healthcare spending, and a large patient population for neurological conditions. Its robust biopharmaceutical industry and advanced diagnostic infrastructure ensure continued market dominance, fostering significant innovation and product adoption.
- Asia-Pacific is projected to be the fastest-growing region in the neurology biomarkers market. This growth is attributed to rising healthcare expenditure, improving diagnostic infrastructure, and increasing awareness of neurological disorders across populous nations like China and India.
- Europe exhibits a notable trend towards collaborative research initiatives and public-private partnerships, primarily targeting neurodegenerative disease biomarkers. This regional strategy aims to accelerate the discovery and validation of crucial diagnostic and prognostic tools, often with significant government and institutional support.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region holds the largest market share due to robust R&D infrastructure, high prevalence of neurological disorders, and significant investment in advanced diagnostic technologies and pharmaceutical development.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This emerging market demonstrates steady growth, influenced by expanding access to healthcare services, increasing incidence of neurological diseases, and growing partnerships for research and development initiatives.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Europe commands a substantial share, driven by well-established healthcare systems, increasing geriatric population, strong academic research, and a supportive regulatory environment for biomarker development.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing rapid growth, this region's market is propelled by improving healthcare infrastructure, rising awareness of neurological conditions, and a large patient pool combined with increasing healthcare expenditure.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- The market in this region is developing, characterized by improving healthcare facilities, a rising focus on early disease diagnosis, and increasing investment in medical tourism and specialized care.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads the neurology biomarkers market due to extensive R&D investments, a robust biotech industry, and a high prevalence of neurological disorders driving demand for advanced diagnostics and treatment monitoring. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil represents the largest healthcare market in South America, with increasing investments in healthcare infrastructure and research, driving the adoption of neurology biomarkers for diverse neurological disorders. |
| 3 | Germany | US$ XX.X Mn | XX.X% | As a leader in European pharmaceuticals and medical technology, Germany benefits from high healthcare expenditure, significant neuroscience research, and a strong focus on advanced diagnostic solutions, including neurology biomarkers. |
| 4 | China | US$ XX.X Mn | XX.X% | China's massive patient pool, rapidly increasing healthcare expenditure, and significant government investment in biotech and neuroscience research are fueling explosive growth in its neurology biomarkers market. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia, the largest healthcare market in the GCC, is witnessing significant government investment in healthcare infrastructure and research, driving demand for advanced diagnostics and neurology biomarkers amidst rising neurological disorder prevalence. |
Countries Covered (26)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Quanterix | XX.X% | Drive ultra-sensitive detection technology adoption for early disease detection and treatment monitoring in neurology. | — | — | Simoa HD-X AnalyzerSimoa SR-X Ultra-Sensitive ReaderSimoa Accelerator Lab Services+1 |
| 2 | C2N Diagnostics | XX.X% | Focus on commercializing blood-based diagnostic tests for Alzheimer's disease. | — | — | PrecivityAD blood testPrecivityAD2 blood testPrecivity-Aβ42/40 ratio |
| 3 | Denali Therapeutics | XX.X% | Develop innovative therapeutics for neurodegenerative diseases by targeting underlying disease biology. | — | — | LRRK2 InhibitorRIPK1 InhibitorsTV-enabled biologics |
| 4 | Alector | XX.X% | Leverage immunology to develop disease-modifying treatments for neurodegenerative disorders. | — | — | AL002AL001AL101 |
| 5 | Prothena | XX.X% | Discover and develop novel therapies for protein misfolding diseases, including neurological conditions. | — | — | PrasinezumabBirtamimabPRX012 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Quanterix, C2N Diagnostics, Denali Therapeutics, Alector, Prothena, Acumen Pharmaceuticals, Voyager Therapeutics, Neurocrine Biosciences, Amprion, Centogene, SomaLogic, Recursion Pharmaceuticals, Invitae, Proteome Sciences, Imeka, Vaxxinity, Cerecin, NeuroSense Therapeutics, Anavex Life Sciences, Cognito Therapeutics
The global Neurology Biomarkers market features a competitive landscape led by Quanterix, C2N Diagnostics, Denali Therapeutics, Alector, Prothena, and Acumen Pharmaceuticals, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Quanterix
C2N Diagnostics
Denali Therapeutics
Alector
Prothena
Acumen Pharmaceuticals
Voyager Therapeutics
Neurocrine Biosciences
Amprion
Centogene
SomaLogic
Recursion Pharmaceuticals
Invitae
Proteome Sciences
Imeka
Vaxxinity
Cerecin
NeuroSense Therapeutics
Anavex Life Sciences
Cognito Therapeutics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Novel Blood Test for Early Alzheimer's Detection Receives Regulatory Approval
A leading diagnostics company has launched a new, minimally invasive blood test for the early detection of Alzheimer's disease, significantly improving accessibility compared to traditional CSF or PET imaging. This development is poised to revolutionize early diagnosis and clinical trial recruitment for AD.
Major Pharma Company Partners with Biotech to Accelerate Parkinson's Biomarker Discovery
A global pharmaceutical giant announced a strategic partnership with a specialized biotech firm to identify and validate novel biomarkers for Parkinson's disease progression and therapeutic response. The collaboration aims to develop companion diagnostics for upcoming disease-modifying therapies.
ALS Biomarker Innovator Secures Multi-Million Dollar Series B Funding
A startup focused on developing liquid biopsy biomarkers for Amyotrophic Lateral Sclerosis (ALS) successfully closed a Series B funding round totaling US$ XX.X. The investment will fuel further R&D and clinical validation of their diagnostic platform, potentially offering earlier and more precise diagnosis for ALS patients.
Global Diagnostics Leader Acquires Specialist in Neuro-Inflammation Biomarkers
A prominent global diagnostics company acquired a smaller firm known for its proprietary assays for neuro-inflammatory biomarkers, crucial for conditions like Multiple Sclerosis and neurodegenerative diseases. This acquisition strengthens the buyer's portfolio in the rapidly expanding neurology diagnostics sector.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $2.4 Bn |
| Market Size (Forecast) | $8.2 Bn |
| CAGR | 13.1% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 26 Countries |
| Segments Covered | 6 Segments, 40 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Neurology Biomarkers Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Neurology Biomarkers market is estimated at $2.4 Bn in 2025. It is forecast to reach $8.2 Bn in 2035.
The Neurology Biomarkers market is forecast to grow at a CAGR of 13.1% from 2025 to 2035.
The main segments include Type (e.g., Amyloid Beta, Tau Protein), Technology (e.g., Immunoassays, Mass Spectrometry), Application (e.g., Alzheimer's Disease, Parkinson's Disease), End-User (e.g., Pharmaceutical & Biotechnology Companies), Source (e.g., Cerebrospinal Fluid, Blood), and Product & Service (e.g., Assay Kits, Analyzers & Instruments).
Leading companies in this market include Quanterix, C2N Diagnostics, Denali Therapeutics, Alector, Prothena, Acumen Pharmaceuticals, Voyager Therapeutics, Neurocrine Biosciences, Amprion, Centogene, SomaLogic, and Recursion Pharmaceuticals.
The report covers market sizing and forecasts from 2025 to 2035, global geographic coverage, and analysis by biomarker type, disease indication, end-user, and technology. It focuses on pharmaceutical R&D and diagnostic applications within neurology.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Neurology Therapeutics Market
$118.0 Bn in 2025 · 5.2% CAGR
Cancer Biomarkers Market
$25.0 Bn in 2025 · 10.0% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR
AI Bioengineering Market
$2.7 Bn in 2025 · 25.5% CAGR
AI Bioinformatics Platform Market
$1.7 Bn in 2025 · 22.8% CAGR
AI Biomanufacturing Intelligence Market
$684.0 Mn in 2025 · 25.1% CAGR
AI Biomarker Discovery Market
$900.0 Mn in 2025 · 10.3% CAGR
AI Biomolecule Design Market
$200.0 Mn in 2025 · 17.5% CAGR